AI Article Synopsis

  • Sri Lanka's National Programme for Elimination of Lymphatic Filariasis (NPELF) was launched in 2002, yielding significant success with five years of mass drug administration leading to the WHO’s validation of elimination of the disease as a public health problem by 2016.
  • A study analyzing data from 2006 to 2022 revealed that in 2022 there were 566 new lymphoedema cases, with most patients in early stages of the disease, particularly in the Western Province.
  • The overall rates of lymphoedema and hospital admissions for related conditions demonstrated a consistent decline, with a notable yearly reduction of 7.6% from 2007 to 2022, underscoring the

Article Abstract

Introduction: Sri Lanka implemented the National Programme for Elimination of Lymphatic Filariasis (NPELF) in its endemic regions in 2002. Five annual rounds of mass drug administration using the two-drug combination diethylcarbamazine (DEC) and albendazole led to sustained reductions in infection rates below threshold levels. In 2016, WHO validated that Sri Lanka eliminated lymphatic filariasis as a public health problem.

Objective: To explore the impact of the NPELF on lymphatic filariasis morbidity in Sri Lanka.

Methods: Passive Case Detection (PCD) data maintained in filaria clinic registries from 2006-2022 for lymphoedema and hospital admission data for managing hydroceles/spermatoceles from 2007-2022 were analyzed. The morbidity status in 2022 and trends in overall and district-wise PCD rates were assessed. Poisson log-linear models were used to assess the trends in PCD for endemic regions, including district-wise trends and hospital admissions for the management of hydroceles/spermatoceles.

Results: In 2022, there were 566 new lymphoedema case visits. The mean (SD) age was 53.9 (16.0) years. The staging was done for 94% of cases, of which 79% were in the early stages (57.3% and 21.4% in stages two and one, respectively). Western Province had the highest caseload (52%), followed by the Southern (32%) and Northwestern (16%) Provinces, respectively. The reported lymphoedema PCD rate in 2022 was 0.61 per 10,000 endemic population. The overall PCD rate showed a decline of 7.6% (95%CI: 4.9% - 10.3%) per year (P < 0.0001) from 2007 to 2022. A steady decline was observed in Colombo, Gampaha and Kurunegala districts, while Kalutara remained static and other districts showed a decline in recent years. Further, admissions for inpatient management of hydroceles/spermatoceles showed a declining trend after 2015.

Conclusions: The PCD rates of lymphoedema and hydroceles/spermatoceles showed a declining trend in Sri Lanka after the implementation of the NPELF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324254PMC
http://dx.doi.org/10.1371/journal.pntd.0012343DOI Listing

Publication Analysis

Top Keywords

lymphatic filariasis
20
sri lanka
16
national programme
8
filariasis morbidity
8
morbidity sri
8
elimination lymphatic
8
filariasis public
8
public health
8
endemic regions
8
pcd rates
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!